Reference

1. National Cancer Institute. What Is Cancer? [Internet]. Bethesda (MD): National Cancer Institute; 2021 [cited 2023 Aug 2]. 
2. American Cancer Society. Breast Cancer Overview. [Internet]. Atlanta (GA): American Cancer Society; 2021 [cited 2023 Aug 2]. 
3. National Cancer Institute. Breast Cancer Treatment (PDQ®)–Patient Version. [Internet]. Bethesda (MD): National Cancer Institute; 2021 [cited 2023 Aug 2]. 
4. American Cancer Society. Breast Cancer HER2 Status. [Internet]. Atlanta (GA): American Cancer Society; 2021 [cited 2023 Aug 2]. 
5. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62. 
6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. 
7. American Cancer Society. Breast Cancer Facts & Figures 2021-2022. [Internet]. Atlanta (GA): American Cancer Society; 2021 [cited 2023 Aug 2]. 
8. Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289-295. 
9. Breast cancer incidence highest in India: Expert. [Internet]. The Times of India; 2022 [cited 2023 Aug 2]. 
10. Sofi NY. Breast cancer in India: Where do we stand and where do we go? South Asian J Cancer. 2020;9(1):1-2. 
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. 
12. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, King MC. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. 
13. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Stratton MR. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792. 
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047-1059. 
15. Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjörd JE, Hopper JL, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130. 
16. American Cancer Society. Breast Cancer Risk Factors. [Internet]. Atlanta (GA): American Cancer Society; [cited 2023 Aug 2]. 
17. Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87(11):1234-1245. 
18. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141- 1151. 
19. American Cancer Society. Signs and Symptoms of Breast Cancer. [Internet]. Atlanta (GA): American Cancer Society; 2021 [cited 2023 Aug 2]. 
20. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Beck AH. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-2122. 
21. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Slamon DJ. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines With FISH scores used for enrollment in breast cancer international research group clinical trials. J Clin Oncol. 2016;34(29):3518-3528. 
22. Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Lehr HA. The assessment of HER2 status in breast carcinomas: the past, the present, and the future. Pathol Oncol Res. 2013;19(2):217-224. 
23. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25-38.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137. 
25. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282-303. 
26. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62. 
27. Houssami et al. Meta-analysis of the Impact of Surgical Margins on Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Therapy. Eur J Cancer. 2020;127:31-39. 
28. Smith et al. Fractionation of Whole Breast Radiation Therapy in Breast Conservation Therapy for Early-Stage Breast Cancer: An Updated Meta-analysis. Int J Radiat Oncol Biol Phys. 2019;104(1):50-60. 
29. Sledge et al. Monarch 1: Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2014;36(24):2465-2472. 
30. Tolaney et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomised Study. Lancet Oncol. 2019;20(7):917-930. 
31. Johnston et al. MONARCH 3 Final PFS: A Randomized Study of Abemaciclib as Initial Therapy for Advanced Breast Cancer. NPJ Breast Cancer. 2019;5(1):5. 
32. Denlinger et al. Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014. J Natl Compr Canc Netw. 2014;12(10):1526-1531.